Is The Santa Claus Rally The Gift That Keeps Giving?
Remember the horror of 2008 when the Great Recession hit…
Sell
13
HCM Quote, Financials, Valuation and Earnings
Last price:
$14.28
Seasonality move
:
-6.59%
Day range:
$14.23 - $14.35
52-week range:
$11.93 - $21.92
Dividend yield:
0%
P/E ratio:
30.00x
P/S ratio:
5.93x
P/B ratio:
3.30x
Volume:
12.5K
Avg. volume:
68.9K
1-year change:
-15.13%
Market cap:
$2.4B
Revenue:
$838M
EPS (TTM):
-$0.25
Analysts' Opinion
-
Consensus RatingHUTCHMED (China) has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $28.11, HUTCHMED (China) has an estimated upside of 96.54% from its current price of $14.30.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $17.50 representing 100% downside risk from its current price of $14.30.
Fair Value
-
According to the consensus of 11 analysts, HUTCHMED (China) has 96.54% upside to fair value with a price target of $28.11 per share.
HCM vs. S&P 500
-
Over the past 5 trading days, HUTCHMED (China) has underperformed the S&P 500 by -6.52% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
HUTCHMED (China) does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
HUTCHMED (China) has grown year-over-year revenues for 3 quarters straight. In the most recent quarter HUTCHMED (China) reported revenues of --.
Earnings Growth
-
HUTCHMED (China) has grown year-over-year earnings for 0 quarters straight. In the most recent quarter HUTCHMED (China) reported earnings per share of --.
Enterprise value:
1.7B
EV / Invested capital:
--
Price / LTM sales:
5.93x
EV / EBIT:
34.25x
EV / Revenue:
4.13x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-26.56x
Price / Operating cash flow:
15.37x
Enterprise value / EBITDA:
30.07x
Gross Profit (TTM):
$64M
Return On Assets:
-3.28%
Net Income Margin (TTM):
-9.99%
Return On Equity:
-5.49%
Return On Invested Capital:
-5.04%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2020-06-30 | 2021-06-30 | |
| Income Statement | ||||||
| Revenue | $204.4M | $209M | $264.1M | $55.2M | $75.8M | |
| Gross Profit | -- | -- | -- | $12.9M | $17.5M | |
| Operating Income | -- | -- | -- | -$45.7M | -$80.5M | |
| EBITDA | -- | -- | -- | -$45.7M | -$80.5M | |
| Diluted EPS | -- | -- | -- | -$0.25 | -$0.40 | |
| Period Ending | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $374.7M | $1.1B | $1B | $1.1B | $1B | |
| Total Assets | $525.6M | $1.3B | $1.2B | $1.3B | $1.3B | |
| Current Liabilities | $119.4M | $247.7M | $321.9M | $340.9M | $401.4M | |
| Total Liabilities | $158.5M | $259.2M | $342.5M | $497.5M | $508.9M | |
| Total Equity | $367M | $1B | $851.8M | $800M | $752M | |
| Total Debt | -- | -- | $418K | $40.1M | $82.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2020-06-30 | 2021-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$48.6M | -$58.4M | -$99.7M | -$26.6M | -$49M | |
| Cash From Investing | -- | -- | -- | -$41.3M | -$315.9M | |
| Cash From Financing | -- | -- | -- | -$14.4M | $605.1M | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
HCM
Sector
Market Cap
$2.4B
$46.1M
Price % of 52-Week High
65.24%
46.02%
Dividend Yield
0%
0%
Shareholder Yield
0.36%
-0.6%
1-Year Price Total Return
-15.13%
-30.52%
Beta (5-Year)
0.781
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$14.66
200-day SMA
Sell
Level
$18.11
Bollinger Bands (100)
Sell
Level
16.31 - 19.73
Chaikin Money Flow
Buy
Level
20.9M
20-day SMA
Sell
Level
$16.11
Relative Strength Index (RSI14)
Sell
Level
29.27
ADX Line
Sell
Level
17.92
Williams %R
Buy
Level
-92.3664
50-day SMA
Sell
Level
$17.67
MACD (12, 26)
Sell
Level
-0.96
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
15.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.9636)
Buy
CA Score
(Annual)
Level (0.4207)
Buy
Beneish M-Score
(Annual)
Level (-2.7002)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-3.4826)
Buy
Piotroski F Score
(Annual)
Level (8)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Stock Forecast FAQ
In the current month, HCM has received 9 Buy ratings 2 Hold ratings, and 0 Sell ratings. The HCM average analyst price target in the past 3 months is $28.11.
-
Where Will HUTCHMED (China) Stock Be In 1 Year?
According to analysts, the consensus estimate is that HUTCHMED (China) share price will rise to $28.11 per share over the next 12 months.
-
What Do Analysts Say About HUTCHMED (China)?
Analysts are divided on their view about HUTCHMED (China) share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that HUTCHMED (China) is a Sell and believe this share price will drop from its current level to $17.50.
-
What Is HUTCHMED (China)'s Price Target?
The price target for HUTCHMED (China) over the next 1-year time period is forecast to be $28.11 according to 11 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is HCM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for HUTCHMED (China) is a Buy. 9 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of HCM?
You can purchase shares of HUTCHMED (China) via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase HUTCHMED (China) shares.
-
What Is The HUTCHMED (China) Share Price Today?
HUTCHMED (China) was last trading at $14.28 per share. This represents the most recent stock quote for HUTCHMED (China). Yesterday, HUTCHMED (China) closed at $14.30 per share.
-
How To Buy HUTCHMED (China) Stock Online?
In order to purchase HUTCHMED (China) stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Alphabet an Undervalued Growth Stock to Buy?
Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…
Is Tesla Going to Buy Uber?
Tesla has always been in the habit of making large,…
Stock Ideas
Buy
65
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
57
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 118x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 37x
Alerts
Buy
87
PSIX alert for Dec 25
Power Solutions International [PSIX] is up 27.42% over the past day.
Buy
65
TSLL alert for Dec 25
Direxion Daily TSLA Bull 2X Shares [TSLL] is up 19.46% over the past day.
Buy
75
SMLR alert for Dec 25
Semler Scientific [SMLR] is up 15.37% over the past day.
